Sinovac Obtains Trial Approval for Polio Vaccine in China

Sinovac Biotech, a Beijing vaccine company, was granted CFDA approval to begin clinical trials of its Sabin Inactivated Polio Vaccine (sIPV) candidate. China, like most countries, wants to eliminate the use of oral polio vaccines, because they sometimes (though rarely) cause the disease. Sinovac licensed the vaccine from Intravac (Institute for Translational Vaccinology) of the Netherlands. The sIPV is in short supply globally and represents a potential export opportunity for Sinovac. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //